Champions Oncology, Inc.

NasdaqCM:CSBR 株式レポート

時価総額:US$67.2m

このページの翻訳は実験的なもので、現在開発中です。お待ちしております!

Champions Oncology 将来の成長

Future 基準チェック /16

Champions Oncologyは収益が増加すると予測されています。

主要情報

n/a

収益成長率

n/a

EPS成長率

Life Sciences 収益成長16.7%
収益成長率11.6%
将来の株主資本利益率n/a
アナリストカバレッジ

Low

最終更新日13 Mar 2024

今後の成長に関する最新情報

Recent updates

It's A Story Of Risk Vs Reward With Champions Oncology, Inc. (NASDAQ:CSBR)

Jun 14
It's A Story Of Risk Vs Reward With Champions Oncology, Inc. (NASDAQ:CSBR)

Is Now The Time To Put Champions Oncology (NASDAQ:CSBR) On Your Watchlist?

Sep 28
Is Now The Time To Put Champions Oncology (NASDAQ:CSBR) On Your Watchlist?

Champions Oncology Non-GAAP EPS of -$0.02, revenue of $12.9M

Jul 21

We Think Some Shareholders May Hesitate To Increase Champions Oncology, Inc.'s (NASDAQ:CSBR) CEO Compensation

Oct 14
We Think Some Shareholders May Hesitate To Increase Champions Oncology, Inc.'s (NASDAQ:CSBR) CEO Compensation

We Think Champions Oncology (NASDAQ:CSBR) Can Afford To Drive Business Growth

Jun 21
We Think Champions Oncology (NASDAQ:CSBR) Can Afford To Drive Business Growth

Are Investors Undervaluing Champions Oncology, Inc. (NASDAQ:CSBR) By 44%?

Apr 09
Are Investors Undervaluing Champions Oncology, Inc. (NASDAQ:CSBR) By 44%?

Here's Why We're Not At All Concerned With Champions Oncology's (NASDAQ:CSBR) Cash Burn Situation

Mar 19
Here's Why We're Not At All Concerned With Champions Oncology's (NASDAQ:CSBR) Cash Burn Situation

The Champions Oncology (NASDAQ:CSBR) Share Price Has Gained 243%, So Why Not Pay It Some Attention?

Mar 02
The Champions Oncology (NASDAQ:CSBR) Share Price Has Gained 243%, So Why Not Pay It Some Attention?

Is There Now An Opportunity In Champions Oncology, Inc. (NASDAQ:CSBR)?

Feb 04
Is There Now An Opportunity In Champions Oncology, Inc. (NASDAQ:CSBR)?

Do Insiders Own Lots Of Shares In Champions Oncology, Inc. (NASDAQ:CSBR)?

Jan 14
Do Insiders Own Lots Of Shares In Champions Oncology, Inc. (NASDAQ:CSBR)?

Philip Breitfeld Is The Chief Strategy & Innovation Officer and Director of Champions Oncology, Inc. (NASDAQ:CSBR) And They Just Sold 100% Of Their Shares

Dec 19
Philip Breitfeld Is The Chief Strategy & Innovation Officer and Director of Champions Oncology, Inc. (NASDAQ:CSBR) And They Just Sold 100% Of Their Shares

Champions Oncology, Inc. (NASDAQ:CSBR) Analysts Are Pretty Bullish On The Stock After Recent Results

Dec 16
Champions Oncology, Inc. (NASDAQ:CSBR) Analysts Are Pretty Bullish On The Stock After Recent Results

Champions Oncology beats on revenue

Dec 14

Estimating The Fair Value Of Champions Oncology, Inc. (NASDAQ:CSBR)

Dec 04
Estimating The Fair Value Of Champions Oncology, Inc. (NASDAQ:CSBR)

業績と収益の成長予測

NasdaqCM:CSBR - アナリストの将来予測と過去の財務データ ( )USD Millions
日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数
4/30/202767N/A0N/A1
4/30/202659N/A-3N/A1
4/30/202554N/A-7N/A1
4/30/202449N/A-8N/A1
1/31/202449-10-7-5N/A
10/31/202350-10-5-3N/A
7/31/202353-8-30N/A
4/30/202354-514N/A
1/31/202354-335N/A
10/31/202254068N/A
7/31/202252046N/A
4/30/202249146N/A
1/31/202247014N/A
10/31/2021440-40N/A
7/31/2021430-4-1N/A
4/30/2021410-5-2N/A
1/31/202139-1-13N/A
10/31/202037-203N/A
7/31/202035-102N/A
4/30/202032-213N/A
1/31/202031001N/A
10/31/201929-112N/A
7/31/201928-101N/A
4/30/201927012N/A
1/31/201924012N/A
10/31/201823001N/A
7/31/201821011N/A
4/30/201820-1-2-1N/A
1/31/201819-3-2-1N/A
10/31/201718-5N/A-2N/A
7/31/201717-5N/A-2N/A
4/30/201715-7N/A-3N/A
1/31/201715-7N/A-4N/A
10/31/201614-8N/A-4N/A
7/31/201612-10N/A-6N/A
4/30/201611-10N/A-6N/A
1/31/201612-12N/A-8N/A
10/31/201511-12N/A-10N/A
7/31/201510-13N/A-9N/A
4/30/20159-13N/A-10N/A
1/31/20158-12N/A-7N/A
10/31/201410-10N/A-7N/A
7/31/201410-9N/A-4N/A
4/30/201412-7N/A-3N/A
1/31/201411-7N/A-5N/A
10/31/201310-8N/A-4N/A
7/31/20139-7N/A-5N/A

アナリストによる今後の成長予測

収入対貯蓄率: CSBRの予測収益成長が 貯蓄率 ( 2.4% ) を上回っているかどうかを判断するにはデータが不十分です。

収益対市場: CSBRの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です

高成長収益: CSBRの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。

収益対市場: CSBRの収益 ( 11.6% ) US市場 ( 8.7% ) よりも速いペースで成長すると予測されています。

高い収益成長: CSBRの収益 ( 11.6% ) 20%よりも低い成長が予測されています。


一株当たり利益成長率予想


将来の株主資本利益率

将来のROE: CSBRの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です


成長企業の発掘